Business Planning
How Partnering With Your Cardiovascular Service Line Administrator Can Help You Launch a Successful Program
Recorded September 24, 2025
Launching a new therapeutic program is a complicated process, fraught with pitfalls. Understanding when and how to engage with other stakeholders can help avoid costly errors.
By embracing a collaborative approach, you can lead a successful program. Start by working with your cardiovascular service line administrator on your business plan.
If you let them, they can help you:
- Demonstrate the potential for improved patient outcomes and long-term cost savings by reducing cardiovascular-related complications associated with high blood pressure
- Calculate cost estimates, such as the upfront acquisition of technology
- Set up training programs
- Integrate your program with existing clinical workflows
- Define appropriate patient selection criteria
- Navigate reimbursement policies
- Develop pricing strategies and revenue projections
- Promote your program
Watch ”How Interventional Cardiologists Can Partner Wth Their Cardiovascular Service Line Administrators to Put Together a Successful Business Plan to Launch a Renal Denervation (RDN) Program” to learn more.
Featuring Atul Chugh, MD, Kintur A. Sanghvi, MD, FSCAI, and Eric Secemsky, MD, FSCAI.
Part of SCAI's Clinical Conversations in Interventional Cardiology series.
Program Building
Taking Your Next Steps
Recorded May 1, 2025
Catch up on our workshop, "Building a Renal Denervation Program," which takes a deeper dive into program building: exploring resistant hypertension (rHTN), the evidence landscape surrounding RDN, operational and administrative program requirements, and how to perform the procedure.
Practice Management
General Coding Guidelines
The Centers for Medicare and Medicaid Services published their final National Coverage Determination (NCD) covering radiofrequency and ultrasound renal denervation on October 28, 2025. The document below summarizes the requirements.
Two Category 3 CPT codes apply to renal denervation, which leave the Medicare Administrative Contractors (MACs) and commercial payers to carrier price the procedures.
Inpatient and Outpatient Facility Payments
Hospital payment processes for inpatient and outpatient procedures differ for new devices. Use these tip sheets to understand the codes and processes for each.
Need Help?
Please ask us your renal denervation coding and billing questions.
Clinical Documentation
2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults
A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
August 14, 2025
The focus of this clinical practice guideline is to create a living, working document updating current knowledge in the field of high blood pressure aimed at all practicing primary care and specialty clinicians who manage patients with hypertension.
This guideline replaces the previous version from 2017 and reflects the latest research and evidence since February 2015 on the prevention, detection, evaluation and management of high blood pressure in adults.
Among the major changes included in the guideline, several new or revised recommendations address topics including resistant hypertension and renal denervation.
SCAI Position Statement on Renal Denervation for Hypertension
Patient Selection, Best Practices for Optimal Techniques, Competence, Training, and Organizational Recommendations
August 21, 2023
Despite efforts to manage HTN through medication and lifestyle changes, over half of those with high blood pressure fail to meet treatment goals. Medical therapy is hindered by issues like cost, side effects, access limitations, and adherence problems. RDN offers a minimally invasive solution by targeting nerves near the renal arteries. Clinical trials reveal that disrupting these nerves reduces blood pressure safely in the short term, with evidence suggesting lasting effects.
In 2021, SCAI and the National Kidney Foundation jointly published an expert consensus statement, which discusses HTN control history, trial data, multidisciplinary assessments, and patient-centered decisions for potential RDN candidates.
This 2023 SCAI statement aims to standardize protocols and enhance procedural outcomes, and covers patient selection, procedural insights, operator training, and institutional requirements for successful implementation.
Proceedings from Expert Consensus Roundtable on Renal Denervation Treatment for Use in Hypertension Patients
August 5, 2021
This document reflects discussions from a multi-disciplinary roundtable on the possible role of renal denervation (RDN) as a therapeutic option to complement medical therapy and lifestyle interventions for patients with uncontrolled hypertension. The paper outlines consensus view on issues related to blood pressure control and associated risk, evaluation, and treatment pathways for hypertension, RDN safety and effectiveness, and how RDN may be incorporated into clinical practice. The expert panel consisted of hypertension specialists, nephrologists, general cardiologists, and interventional cardiologists. The roundtable was co-sponsored by SCAI and the National Kidney Foundation
JSCAI Articles and Editorials
- Cost-Utility Analysis of Endovascular Ultrasound Renal Denervation to Treat Resistant Hypertension in the United States
- Catheter-Based Radiofrequency Renal Denervation in the United States: A Cost-Effectiveness Analysis Based on Contemporary Evidence
- Balancing Affordability and Need: Should We Use Renal Denervation in Hypertension Management?
- Renal Denervation for Treatment of Hypertension: From High-Level Quality Evidence to Implementation in Clinical Practice
News and Clinical Trial Coverage
- RADIANCE-HTN—Coverage of TCT 2021 | SCAI
- SCAI Guidelines on Device Selection in Aorto-Iliac Arterial Interventions
- Efficacy and Safety of Intravascular Lithotripsy for the Treatment of Peripheral Arterial Disease: An Individual Patient‐Level Pooled Data Analysis
- Outcomes and Safety of Concurrent Coronary and Peripheral Catheterization (REVascularization in Concomitant PERIpheral Artery Disease and Coronary Artery Disease REV-PERICAD Study)